PT756595E - 1,3-oxatiolanos substituidos com propriedades anti-virais - Google Patents
1,3-oxatiolanos substituidos com propriedades anti-viraisInfo
- Publication number
- PT756595E PT756595E PT95915098T PT95915098T PT756595E PT 756595 E PT756595 E PT 756595E PT 95915098 T PT95915098 T PT 95915098T PT 95915098 T PT95915098 T PT 95915098T PT 756595 E PT756595 E PT 756595E
- Authority
- PT
- Portugal
- Prior art keywords
- substituted
- oxatiolanos
- viral properties
- relates
- viral
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical class C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical group NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 abstract 1
- 229960004413 flucytosine Drugs 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/230,317 US5587480A (en) | 1990-11-13 | 1994-04-20 | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT756595E true PT756595E (pt) | 2002-08-30 |
Family
ID=22864746
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01118810T PT1153924E (pt) | 1994-04-20 | 1995-04-19 | 1,3-oxatiolanos substituidos com propriedades anti-virais |
| PT04018075T PT1473294E (pt) | 1994-04-20 | 1995-04-19 | 1,3-oxatiolanos substituídos com propriedades antivirais. |
| PT95915098T PT756595E (pt) | 1994-04-20 | 1995-04-19 | 1,3-oxatiolanos substituidos com propriedades anti-virais |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01118810T PT1153924E (pt) | 1994-04-20 | 1995-04-19 | 1,3-oxatiolanos substituidos com propriedades anti-virais |
| PT04018075T PT1473294E (pt) | 1994-04-20 | 1995-04-19 | 1,3-oxatiolanos substituídos com propriedades antivirais. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5587480A (pt) |
| EP (3) | EP1153924B1 (pt) |
| JP (1) | JPH09512526A (pt) |
| AT (3) | ATE360019T1 (pt) |
| AU (1) | AU693884B2 (pt) |
| CA (1) | CA2188283C (pt) |
| DE (3) | DE69525742T2 (pt) |
| DK (3) | DK1473294T3 (pt) |
| ES (3) | ES2172580T3 (pt) |
| HK (3) | HK1041487B (pt) |
| PT (3) | PT1153924E (pt) |
| WO (1) | WO1995029176A1 (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US5728575A (en) * | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
| US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US6369066B1 (en) | 1990-11-13 | 2002-04-09 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes with antiviral properties |
| US6228860B1 (en) * | 1990-11-13 | 2001-05-08 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes with antiviral properties |
| US20050192299A1 (en) * | 1992-04-16 | 2005-09-01 | Yung-Chi Cheng | Method of treating or preventing hepatitis B virus |
| US20020120130A1 (en) * | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
| IL113432A (en) | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
| WO1996040164A1 (en) * | 1995-06-07 | 1996-12-19 | Emory University | Nucleosides with anti-hepatitis b virus activity |
| DE69921829T2 (de) | 1998-08-12 | 2005-10-27 | Gilead Sciences, Inc., Foster City | Verfahren zur herstellung von 1,3-oxathiolannukleoside |
| US6979561B1 (en) | 1998-10-09 | 2005-12-27 | Gilead Sciences, Inc. | Non-homogeneous systems for the resolution of enantiomeric mixtures |
| KR100517163B1 (ko) * | 2000-02-10 | 2005-09-26 | 미쯔이카가쿠 가부시기가이샤 | 1-인산화 당유도체 아노머의 선택적인 제조방법 및뉴클레오사이드의 제조방법 |
| WO2002051852A1 (fr) * | 2000-12-27 | 2002-07-04 | Mitsui Chemicals, Inc. | Procede de production d'un derive de saccharide non naturel |
| CA2449338C (en) * | 2001-06-15 | 2012-02-07 | Shire Biochem Inc. | Stereoselective method for the preparation of nucleoside analogues |
| US20060246130A1 (en) | 2003-01-14 | 2006-11-02 | Dahl Terrence C | Compositions and methods for combination antiviral therapy |
| US7501514B1 (en) | 2003-10-15 | 2009-03-10 | Shire Biochem, Inc. | Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides |
| US7968703B2 (en) | 2005-03-07 | 2011-06-28 | Shire Canada Inc. | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof |
| JP5001254B2 (ja) * | 2005-03-14 | 2012-08-15 | シャイアー カナダ インコーポレイテッド | 光学的に活性なｃｉｓ−２−ヒドロキシメチル−４−（シトシン−１’−イル）−１，３−オキサチオランまたはその薬学的に許容される塩の製造方法 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| WO2008118879A2 (en) * | 2007-03-23 | 2008-10-02 | Ardea Biosciences, Inc. | Antiviral compositions comprising 2 compounds |
| NZ584193A (en) * | 2007-09-28 | 2011-07-29 | Avexa Ltd | A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes |
| EP2346890B1 (en) | 2008-09-05 | 2013-03-20 | Shire Canada Inc. | Enantiomeric resolution of 2,4-disubstituted 1,3-oxathiolane nucleosides |
| US8153416B2 (en) | 2008-12-10 | 2012-04-10 | Thesis Chemistry, Llc | Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes using enzymatic resolution |
| US8431699B2 (en) | 2009-02-27 | 2013-04-30 | Vertichem Corporation | Method for manufacture of 2-oxoimidazolidines |
| TW201131192A (en) * | 2010-03-01 | 2011-09-16 | Univ Nat Central | A co-crystal compound of optical devices |
| EP2780007A4 (en) * | 2011-11-18 | 2015-07-29 | Avexa Ltd | POLY THERAPY WITH APRICITABINE AND PI |
| JP2012136526A (ja) * | 2012-02-09 | 2012-07-19 | Shire Canada Inc | 光学的に活性なｃｉｓ−２−ヒドロキシメチル−４−（シトシン−１’−イル）−１，３−オキサチオランまたはその薬学的に許容される塩の製造方法 |
| WO2024016639A1 (zh) * | 2022-07-21 | 2024-01-25 | 华创合成制药股份有限公司 | 一种抗病毒感染的化合物及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4000137A (en) * | 1975-06-10 | 1976-12-28 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized nucleosides |
| JPS5668674A (en) * | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
| DE3529263A1 (de) * | 1985-08-16 | 1987-02-19 | Hoechst Ag | Verfahren zur herstellung von 2-oxo-1,3-dioxolanen |
| US5159067A (en) * | 1987-01-28 | 1992-10-27 | University Of Georgia Research Foundation Inc. | 5'-Diphosphohexose nucleoside pharmaceutical compositions |
| SE8701605D0 (sv) * | 1987-04-16 | 1987-04-16 | Astra Ab | Novel medicinal compounds |
| US5039667A (en) * | 1987-08-07 | 1991-08-13 | The Governors Of The University Of Alberta | Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides |
| US4997926A (en) * | 1987-11-18 | 1991-03-05 | Scripps Clinic And Research Foundation | Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy |
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
| GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| DE3827134A1 (de) * | 1988-08-10 | 1990-03-15 | Bayer Ag | Substituierte triazolyl- bzw. imidazolyl-hydroxyalkyldioxolane, verfahren zu ihrer herstellung und ihre verwendung als mikrobizide, oxiranyldioxolane, dioxolanylketone, oxiranylketone und (alpha)-halogenketone als zwischenprodukte und verfahren zu deren herstellung |
| NZ233197A (en) * | 1989-04-13 | 1991-11-26 | Richard Thomas Walker | Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions |
| US5118672A (en) * | 1989-07-10 | 1992-06-02 | University Of Georgia Research Foundation | 5'-diphosphohexose nucleoside pharmaceutical compositions |
| NZ234534A (en) * | 1989-07-17 | 1994-12-22 | Univ Birmingham | Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor |
| AU8864191A (en) * | 1990-11-13 | 1992-06-11 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
| ZA923640B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
-
1994
- 1994-04-20 US US08/230,317 patent/US5587480A/en not_active Expired - Lifetime
-
1995
- 1995-04-19 EP EP01118810A patent/EP1153924B1/en not_active Expired - Lifetime
- 1995-04-19 CA CA002188283A patent/CA2188283C/en not_active Expired - Lifetime
- 1995-04-19 AT AT04018075T patent/ATE360019T1/de active
- 1995-04-19 DK DK04018075T patent/DK1473294T3/da active
- 1995-04-19 WO PCT/CA1995/000212 patent/WO1995029176A1/en active IP Right Grant
- 1995-04-19 EP EP04018075A patent/EP1473294B1/en not_active Expired - Lifetime
- 1995-04-19 AT AT01118810T patent/ATE275144T1/de active
- 1995-04-19 AU AU22118/95A patent/AU693884B2/en not_active Expired
- 1995-04-19 PT PT01118810T patent/PT1153924E/pt unknown
- 1995-04-19 PT PT04018075T patent/PT1473294E/pt unknown
- 1995-04-19 JP JP7527244A patent/JPH09512526A/ja active Pending
- 1995-04-19 EP EP95915098A patent/EP0756595B1/en not_active Expired - Lifetime
- 1995-04-19 DE DE69525742T patent/DE69525742T2/de not_active Expired - Lifetime
- 1995-04-19 DK DK95915098T patent/DK0756595T3/da active
- 1995-04-19 ES ES95915098T patent/ES2172580T3/es not_active Expired - Lifetime
- 1995-04-19 PT PT95915098T patent/PT756595E/pt unknown
- 1995-04-19 DE DE69535476T patent/DE69535476T2/de not_active Expired - Lifetime
- 1995-04-19 AT AT95915098T patent/ATE214066T1/de active
- 1995-04-19 DE DE69533458T patent/DE69533458T2/de not_active Expired - Lifetime
- 1995-04-19 ES ES01118810T patent/ES2228714T3/es not_active Expired - Lifetime
- 1995-04-19 ES ES04018075T patent/ES2286542T3/es not_active Expired - Lifetime
-
1998
- 1998-05-29 HK HK02103168.8A patent/HK1041487B/zh not_active IP Right Cessation
- 1998-05-29 HK HK98104642A patent/HK1005544A1/xx not_active IP Right Cessation
- 1998-09-23 DK DK02004883.1T patent/DK1224940T4/da active
-
2005
- 2005-04-28 HK HK05103667A patent/HK1073460A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1153924E (pt) | 1,3-oxatiolanos substituidos com propriedades anti-virais | |
| DE60015927D1 (en) | Phenylharnstoff und phenylthioharnstoffderivate | |
| SE9604786D0 (sv) | New compounds | |
| IL101836A0 (en) | Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives | |
| PH25859A (en) | Composition for treatment of ischemic disorder | |
| FR2613365B1 (fr) | Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| DK0573218T3 (da) | 4-carboxyimidazolderivater som angiotensin-II antagonister og deres terapeutiske anvendelse | |
| DE69118064D1 (de) | Diamino-s-Triazinonderivate und diese enthaltende selbstlöschende polymere Zusammensetzungen | |
| IE893956L (en) | Novel compounds | |
| ATE58135T1 (de) | 1,3-oxathianderivate. | |
| NZ229300A (en) | Substituted-2-ethenyl-3,4,5,6-tetrahydrothieno (4,3,2-cf)(3)benzazepine derivatives and pharmaceutical compositions | |
| DE69527854D1 (de) | Derivate substituierter amidinonaphthylester | |
| FI873145A (fi) | Nya tetracykliska indolderivat. | |
| DK0401049T3 (da) | Beta-lactam elastase inhibitorer | |
| ES2081192T3 (es) | Inhibidor de timidina quinasa viral del herpes simple. | |
| FI905922A0 (fi) | Antagonister foer a-adrenerga receptorer. | |
| FI842639A (fi) | Acylderivat av 1,4,3,6-dianhydro- hexitol. |